Bruckner H W, Kalnicki S, Dalton J, Snady H, Schwartz G K, Chesser M R, Lehrer D, Mandeli J, Harpaz N, Janus C
Department of Neoplastic Disease, Mount Sinai Medical Center, New York, New York 10029-6574.
J Clin Gastroenterol. 1993 Apr;16(3):199-203. doi: 10.1097/00004836-199304000-00006.
Twenty consecutive patients with unresectable, locally advanced pancreatic cancer were treated with split courses of radiotherapy (RT) and simultaneous multidrug chemotherapy consisting of 5 fluorouracil, continuous infusion, streptozotocin, and cisplatin. A separate, retrospective study identified a group of 28 contemporary patients with less advanced pancreatic cancers, all of which were successfully resected. The survival rate of the two groups were similar over the first 2 years, although it initially favored the unresectable group. This pattern of survival among patients treated with combined modality therapy provides a basis for new studies. At the two clinical extremes, these include treatment of unresectable tumors previously considered ineligible for this treatment and initial treatment before resection of stage I tumors.
20例无法切除的局部晚期胰腺癌患者接受了分割疗程放疗（RT）以及由5-氟尿嘧啶持续静脉输注、链脲佐菌素和顺铂组成的同步多药化疗。一项单独的回顾性研究确定了一组28例病情较轻的当代胰腺癌患者，所有这些患者均成功接受了手术切除。两组患者在最初2年的生存率相似，尽管最初不可切除组的生存率更高。联合治疗模式患者的这种生存模式为新的研究提供了基础。在两个临床极端情况下，这包括对以前认为不适合这种治疗的不可切除肿瘤进行治疗，以及对I期肿瘤进行手术切除前的初始治疗。
